Skip to main content
SpringerLink
Log in

Impact of molecular profiling on clinical trial design for glioblastoma

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

This review highlights the ways in which molecular and genetic profiling of malignant gliomas has led to intelligent clinical trial design. The review also highlights known resistance mechanisms to conventional therapies in malignant gliomas and potential strategies to overcome these mechanisms with the use of targeted therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Newlands ES, Stevens MF, Wedge SR, et al.:Temozolomide: a review of its discovery, chemical properties, pre-clinical development, and clinical trials.Cancer Treat Rev 1997,23:35–61.

    Article  PubMed  CAS  Google Scholar 

  2. Wedge SR, Porteous JK, Glaser MG, et al.:In vitro evaluation of temozolomide combined with X-irradiation.Anticancer Drugs 1997,8:92–97.

    Article  PubMed  CAS  Google Scholar 

  3. Newlands ES, Blackledge G, Slack RS:Phase I trial of temozolomide (CCRG 81045: M&B 39831:NSC 362856).Br J Cancer 1992,65:287–291.

    PubMed  CAS  Google Scholar 

  4. Yung WK, Albright RE, Olson J, et al.:A phase II study of temozolomide vs. procarbazine in patients with glioblastoma at first relapse.Br J Cancer 2000,83:588–593.

    Article  PubMed  CAS  Google Scholar 

  5. Stupp R, Dietrich PY, Ostermann Kraljevic S, et al.:Promising survival for patients with newly-diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.J Clin Oncol 2002,20:1375–1382

    Article  PubMed  CAS  Google Scholar 

  6. Stupp R, Mason WP, van den Bent MJ, et al.:Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.N Engl J Med 2005,352:987–996.

    Article  PubMed  CAS  Google Scholar 

  7. Hegi ME, Diserens AC, Gorlia T, et al.:MGMT gene silencing and benefit from temozolomide in glioblastoma.N Engl J Med, 2005,352:997–1003.

    Article  PubMed  CAS  Google Scholar 

  8. Hackel PO, Zwick E, Prenzel N, Ullrich A. et al.:Epidermal growth factor receptors: critical mediators of multiple receptor pathways.Curr Opin Cell Biol 1999,11:184–189.

    Article  PubMed  CAS  Google Scholar 

  9. Woodburn JR:The epidermal growth factor receptor and its inhibition in cancer therapy.Pharmacol Ther 1999:82:241–250.

    Article  PubMed  CAS  Google Scholar 

  10. Zwick E, Prenzel N, Ullrich A. et al.:The EGF receptor as central transducer of heterologous signalling systems.Trends Pharmacol Sci 1999,20:408–412.

    Article  PubMed  CAS  Google Scholar 

  11. Maher EA, Furnari FB, Bachoo RM, et al.:Malignant glioma: genetics and biology of a grave matter.Genes Dev 2001.15:1311–1333.

    Article  PubMed  CAS  Google Scholar 

  12. Ang K K, Berkey BA, Tu X, et al.:Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma.Cancer Res 2002,62:7350–7356.

    PubMed  CAS  Google Scholar 

  13. Baselga J, Albanell J:Targeting epidermal growth factor receptor in lung cancer.Curr Oncol Rep 2002,4:317–324.

    Article  PubMed  Google Scholar 

  14. Baselga J:Why the epidermal growth factor receptor? The rationale for cancer therapy.Oncologist 2002,7(Suppl 4):2–8.

    Article  PubMed  CAS  Google Scholar 

  15. Balaban N, Moni J, Shannon M, et al.:The effect of ionizing radiation on signal transduction: antibodies to EGF receptor sensitize A431 cells to radiation.Biochim Biophys Acta 1996,1314:147–156.

    Article  PubMed  CAS  Google Scholar 

  16. Chakravarti A, Dicker A, Mehta M:The contribution of EGFR signaling in human gliomas: a review of preclinical and correlative data.Int J Radiat Oncol Biol Phys 2004,58:927–931.

    PubMed  CAS  Google Scholar 

  17. Chakravarti A, Loeffler JS, Dyson NJ:Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through the continued activation of phosphoinositide 3-kinase signaling.Cancer Res 2002,62:200–207.

    PubMed  CAS  Google Scholar 

  18. Chakravarti A, Chakladar A, Delaney MA, et al.:The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a ras-dependent manner.Cancer Res 2002,62:4307–4315.

    PubMed  CAS  Google Scholar 

  19. Ciardiello F, Bianco R, Damiano V, et al.:Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.Clin Cancer Res 2000,6:3739–3747.

    PubMed  CAS  Google Scholar 

  20. Ciardiello F:Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents.Drugs 2000,60(Suppl 1):25–32; discussion 41–42.

    Article  PubMed  CAS  Google Scholar 

  21. Dent P, Reardon DB, Park JS, et al.:Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death.Mol Biol Cell 1999,10:2493–2506.

    PubMed  CAS  Google Scholar 

  22. Barker FG II, Simmons ML, Chang SM, et al.:EGFR overex-pression and radiation response in glioblastoma multiforme.Int J Radiat Oncol Biol Phys 2001,51:410–418.

    PubMed  CAS  Google Scholar 

  23. Shinojima N, Tada K, Shiraishi S, et al.:Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.Cancer Res 2003,63:6962–6970.

    PubMed  CAS  Google Scholar 

  24. Chakravarti A, Delaney MA, Noll E, et al.:Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas.Clin Cancer Res 2001,7:2387–2395.

    PubMed  CAS  Google Scholar 

  25. Etienne M-C, Formento JL, Lebrun-Frenay C, et al.:Epidermal growth factor receptor and labeling index are independent prognostic factors in glial turmor outcome.Clin Cancer Res 1998,4:2383–2390.

    PubMed  CAS  Google Scholar 

  26. Feldkamp MM, Lala P, Lau N, et al.:Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens.Neurosurgery 1999,45:1442–1453.

    Article  PubMed  CAS  Google Scholar 

  27. Smith JS, Tachibana I, Passe SM, et al.:PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme.J Natl Cancer Inst 2001,93:1246–1256.

    Article  PubMed  CAS  Google Scholar 

  28. Rainov NG, Dobberstein KU, Bahn H:Prognostic factors in malignant glioma: Influence of the overexpression of oncogene and tumor-suppressor gene products on survival.J Neurooncol 1997,35:13–28.

    Article  PubMed  CAS  Google Scholar 

  29. Chakravarti A, Seiferheld W, Tu X, et al.:Immunohistochemically determined total EGFR levels are not of prognostic value in newly diagnosed GBM: A Report from the Radiation Therapy Oncology Group.Int J Radiat Oncol Biol Phys 2005,62:318–327.

    PubMed  CAS  Google Scholar 

  30. Buckner JC, Aldape KD, Ballman K, et al.:Immunohistochemical detection of EGFRvIII and prognostic significance in patients with malignant glioma enrolled in NCCTG clinical trials.J Clin Oncol 2004,22(14S):1505.

    Google Scholar 

  31. Prados M, Yung W, Wen P, et al.:Phase I study of ZD1839 plus temozolomide in patients with malignant glioma.J Clin Oncol 2004,22(14s):1504.

    Google Scholar 

  32. Rich J, Reardon DA, Peery T, et al.: Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004, 22:133–142.

    Article  PubMed  CAS  Google Scholar 

  33. Prados M, Chang S, Burton E, et al.: Phase I study of OSI-774 alone or with temozolomide in patients with malignant glioma [abstract]. Proc ASCO 2003, 22:99.

    Google Scholar 

  34. Chakravarti A, Zhai G, Suzuki Y, et al.: The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol 2004, 22:1926–1933.

    Article  PubMed  CAS  Google Scholar 

  35. Chakravarti A, Loeffler JS, Dyson NJ:Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of physphoinositide 3-kinase signaling.Cancer Res 2002,62:200–207.

    PubMed  CAS  Google Scholar 

  36. Chakravarti A, Seiferfeld W, Robins H, et al.: An update of phase I data from RTOG 0211:A phase I/II clinical study of gefitinib+radiation for newly-diagnosed GBM patients.J Clin Oncol 2004,22(14S):1571.

    Google Scholar 

  37. Galanis E, Buckner JC, Maurer M, al.:NCCTG phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM).J Clin Oncol 2004,22(14S):1503.

    Google Scholar 

  38. Conrad C, Friedman H, Reardon D, et al.:A phase I/II trial of single-agent PTK 787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent GBM.J Clin Oncol 2004,22(14S):1512.

    Google Scholar 

  39. Reardon DA, Friedman HS, Yung WKA, et al.:A phase I/II trial of PTK-787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent GBM.J Clin Oncol 2004,22(14S):1513.

    Google Scholar 

  40. Rich JN, Hans C, Jones B, et al.:Gene expression profiling and genetic markers in glioblastoma survival.Cancer Res 2005,65:4051–4058.

    Article  PubMed  CAS  Google Scholar 

  41. Liang Y, Diehn M, Watson N, et al.:Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme.Proc Natl Acad Sci U S A 2005,102:5814–5819.

    Article  PubMed  CAS  Google Scholar 

  42. Freije WA, Castro-Vargas FE, Fang Z:Gene expression profiles of gliomas strongly predicts survival.Cancer Res 2004,64:6503–6510.

    Article  PubMed  CAS  Google Scholar 

  43. Chakravarti A, Noll E, Black PM, et al.:Quantitatively determined survivin expression levels are of prognostic value in human gliomas.J Clin Oncol 2002,20:1063–1068.

    Article  PubMed  CAS  Google Scholar 

  44. Chakravarti A, Zhai GG, Zhang M, et al.:Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms.Oncogene 2004,23:7494–7506.

    Article  PubMed  CAS  Google Scholar 

  45. Phillips H, Kharbanda S, Chen R, et al.:Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis.Cancer Cell 2006,9:157–173.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Massachusetts General Hospital, 100 Blossom Street, Cox 3, 02114, Boston, MA, USA

    Arnab Chakravarti MD

Authors
  1. Arnab Chakravarti MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Erin Tyndall BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kamalakannan Palanichamy PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Minesh Mehta MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kenneth Aldape MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jay Loeffler MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arnab Chakravarti MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chakravarti, A., Tyndall, E., Palanichamy, K. et al. Impact of molecular profiling on clinical trial design for glioblastoma. Curr Oncol Rep 9, 71–79 (2007). https://doi.org/10.1007/BF02951429

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02951429

Keywords

Search

Navigation